.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Accenture
Cerilliant
Chinese Patent Office
UBS
Deloitte
Daiichi Sankyo
US Department of Justice
Express Scripts
Cantor Fitzgerald

Generated: June 26, 2017

DrugPatentWatch Database Preview

Lifitegrast - Generic Drug Details

« Back to Dashboard

What are the generic sources for lifitegrast and what is the scope of lifitegrast freedom to operate?

Lifitegrast
is the generic ingredient in one branded drug marketed by Shire Dev Llc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lifitegrast has seventy-five patent family members in eighteen countries.

One supplier is listed for this compound.

Summary for Generic Name: lifitegrast

Tradenames:1
Patents:14
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list1
Clinical Trials: see list6
Patent Applications: see list41
Drug Prices:see low prices
DailyMed Link:lifitegrast at DailyMed

Pharmacology for Ingredient: lifitegrast

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes7,790,743► Subscribe ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes9,085,553► SubscribeY ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes8,927,574► SubscribeY ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes8,592,450► Subscribe ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes7,314,938► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: lifitegrast

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,045,457Compositions and methods for treatment► Subscribe
9,045,458Compositions and methods for treatment► Subscribe
9,248,126Modulators of cellular adhesion► Subscribe
8,378,105Crystalline pharmaceutical and methods of preparation and use thereof► Subscribe
8,071,617Modulators of cellular adhesion► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lifitegrast

Country Document Number Estimated Expiration
China101873797► Subscribe
Australia2008317473► Subscribe
Japan2014221808► Subscribe
China102065694► Subscribe
European Patent Office2265125► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Merck
Colorcon
Accenture
McKinsey
UBS
Queensland Health
AstraZeneca
Fish and Richardson
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot